AlloDx Presents Two Research Posters at CCSN 2025

On October 22, the 28th Annual Academic Congress of the Chinese Society of Nephrology (CCSN 2025) officially opened at the Zhengzhou International Convention and Exhibition Center. Under the theme 'Innovation Leads the Future of Kidney Health,' the congress brought together renowned experts and scholars in nephrology from across China to discuss cutting-edge advances in the field. The meeting also marked the 110th anniversary of the Chinese Medical Association and the 45th anniversary of its Nephrology Branch. AlloDx, a national high-tech enterprise focused on precision diagnostics for kidney disease, was invited to participate for the first time and showcased multiple innovative testing products and research achievements.

There were more than 12,000 submissions to this conference, and the poster acceptance rate was less than 10%. Two cutting-edge research studies by AlloDx - "BK virus rapid LAMP detection technology" and "Complement system antigen-antibody dual-targeted adjacent extension analysis technology (AADT-PEA)" were successfully selected for poster presentation, attracting widespread attention from participating experts.

This technology can simultaneously detect 11 complement factors and autoantibodies, outperforming traditional ELISA in linear correlation (R² > 0.996) and detection sensitivity (data from the study), providing an efficient, high-throughput new tool for precise diagnosis of complement-abnormality-related kidney disease.

Based on loop-mediated isothermal amplification (LAMP) technology, a colorimetric method was developed that can complete the detection of BK virus in 20 minutes, with a detection limit of 10⁴ copies/μl, which is much faster than the 5 hours required by traditional detection methods. This technology provides a rapid and sensitive virus monitoring tool for patients after kidney transplantation, which helps early intervention and protection of transplanted kidney function.

Relying on its self-developed core technology and full-chain integrated innovation platform, AlloDx has achieved a closed-loop capability from biomarker discovery, reagent and instrument development, to clinical validation and artificial-intelligence data analysis, and has built core testing products covering multiple dimensions such as genetic risk, precise diagnosis, transplant management, and prognosis evaluation. Its debut at this conference attracted many participants to stop and exchange views.